Gut microbiota‐derived trimethylamine‐N‐oxide inhibits SIRT1 to regulate SM22α‐mediated smooth muscle cell inflammation and promote atherosclerosis progression
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867017186747351040 |
|---|---|
| author | Yajuan Yin Mei Wei Xiufang Jiang Mei Liu Xiaocui Shi Xiao Zhang Le Wang Gang Liu Mingqi Zheng Fangfang Ma |
| author_facet | Yajuan Yin Mei Wei Xiufang Jiang Mei Liu Xiaocui Shi Xiao Zhang Le Wang Gang Liu Mingqi Zheng Fangfang Ma Yajuan Yin Mei Wei Xiufang Jiang Mei Liu Xiaocui Shi Xiao Zhang Le Wang Gang Liu Mingqi Zheng Fangfang Ma |
| collection | Wiley Open Access |
| contents | Gut microbiota‐derived trimethylamine‐N‐oxide inhibits SIRT1 to regulate SM22α‐mediated smooth muscle cell inflammation and promote atherosclerosis progression Yajuan Yin Mei Wei Xiufang Jiang Mei Liu Xiaocui Shi Xiao Zhang Le Wang Gang Liu Mingqi Zheng Fangfang Ma Journal of Cell Communication and Signaling Abstract Atherosclerosis (AS) is a prevalent cardiovascular disease, and emerging evidence highlights the critical role of gut microbiota in its development. Trimethylamine‐N‐oxide (TMAO), a metabolite derived from gut microbiota, is thought to promote AS progression by regulating smooth muscle protein 22‐alpha (SM22α)‐mediated inflammation in vascular smooth muscle cells. This study aims to explore the molecular mechanisms of TMAO in AS through multi‐omics analysis, particularly its effects on SIRT1 inhibition and SM22α modulation. 16S ribosomal RNA sequencing revealed an altered gut microbiota composition in AS mice, characterized by increased Bacteroides and decreased Firmicutes. Metabolomics analysis indicated elevated levels of TMAO in AS mice. Transcriptomic data and cell experiments further confirmed that TMAO promotes AS by regulating SM22α‐mediated inflammation via SIRT1 regulation. These findings suggest that TMAO accelerates progression through the SIRT1 and SM22α‐related pathways, offering novel therapeutic targets for AS intervention. 10.1002/ccs3.70021 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/ccs3.70021 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_ccs3_70021 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Gut microbiota‐derived trimethylamine‐N‐oxide inhibits SIRT1 to regulate SM22α‐mediated smooth muscle cell inflammation and promote atherosclerosis progression Yajuan Yin Mei Wei Xiufang Jiang Mei Liu Xiaocui Shi Xiao Zhang Le Wang Gang Liu Mingqi Zheng Fangfang Ma Journal of Cell Communication and Signaling Gut microbiota‐derived trimethylamine‐N‐oxide inhibits SIRT1 to regulate SM22α‐mediated smooth muscle cell inflammation and promote atherosclerosis progression Yajuan Yin Mei Wei Xiufang Jiang Mei Liu Xiaocui Shi Xiao Zhang Le Wang Gang Liu Mingqi Zheng Fangfang Ma Journal of Cell Communication and Signaling Abstract Atherosclerosis (AS) is a prevalent cardiovascular disease, and emerging evidence highlights the critical role of gut microbiota in its development. Trimethylamine‐N‐oxide (TMAO), a metabolite derived from gut microbiota, is thought to promote AS progression by regulating smooth muscle protein 22‐alpha (SM22α)‐mediated inflammation in vascular smooth muscle cells. This study aims to explore the molecular mechanisms of TMAO in AS through multi‐omics analysis, particularly its effects on SIRT1 inhibition and SM22α modulation. 16S ribosomal RNA sequencing revealed an altered gut microbiota composition in AS mice, characterized by increased Bacteroides and decreased Firmicutes. Metabolomics analysis indicated elevated levels of TMAO in AS mice. Transcriptomic data and cell experiments further confirmed that TMAO promotes AS by regulating SM22α‐mediated inflammation via SIRT1 regulation. These findings suggest that TMAO accelerates progression through the SIRT1 and SM22α‐related pathways, offering novel therapeutic targets for AS intervention. 10.1002/ccs3.70021 http://creativecommons.org/licenses/by/4.0/ |
| title | Gut microbiota‐derived trimethylamine‐N‐oxide inhibits SIRT1 to regulate SM22α‐mediated smooth muscle cell inflammation and promote atherosclerosis progression |
| topic | Journal of Cell Communication and Signaling |
| url | https://onlinelibrary.wiley.com/doi/10.1002/ccs3.70021 |